Michael Lu represents clients in complex commercial and antitrust disputes in federal and state courts throughout the country. His practice focuses on class action defense and multi-jurisdictional litigation at both the trial and appellate levels on behalf of a diverse array of clients, including life sciences companies, technology firms, financial institutions, and state-owned entities. Michael is also actively involved in the Firm's pro bono work, and was recently a member of a White & Case trial team that secured a historic settlement on behalf of special needs schoolchildren in the city of Flint, Michigan in response to the city's lead water crisis.
Defended Boehringer Ingelheim in class action multidistrict litigation arising from an alleged "reverse payment" scheme to delay generic competition to Boehringer's stroke prevention drug, Aggrenox, ultimately resulting in an appellate victory in the Second Circuit US Court of Appeals that upheld the class action settlement.
Representing Pfizer in groundbreaking litigation challenging Johnson & Johnson's multifaceted scheme to maintain its monopoly over its blockbuster drug, Remicade, and foreclose biosimilar competition.
Member of a trial team that defended Allergan/Warner Chilcott in class action litigation alleging the drug maker's unlawful monopolization of the market for oral anti-inflammatory medications. The case resulted in a precedent-setting reversal of the trial court's class certification decision by the First Circuit US Court of Appeals.
Member of a trial team that defended a leading global information services company in data breach litigation arising from a massive cyberattack that affected millions of customers' data.
Represented Facebook as a member of a global litigation team that oversaw and managed Facebook's international civil litigation matters, including those concerning intermediary liability, hate speech, defamation, and consumer class action claims.
Represented a major foreign state-owned financial institution in a regulatory enforcement action brought by the New York State Department of Financial Services related to alleged violations of New York's anti-money laundering laws.